It is not known whether ezetimibe alone passes into breast milk or if it could harm a nursing baby. Large‐scale clinical trials will provide us with more definite answer as to whether ezetimibe treatment can improve fatty liver, and resultantly reduce the risk of progression of liver diseases in patients with the MetS.This study was supported in part by a Grant‐in‐Aid for scientific research (10178102) and a Grant‐in‐Aid from ONO Medical Research Foundation. Select one or more newsletters to continue. Frequency not determined. Feeding high‐fat diet to ZOF rats led to obesity accompanied by hypercholesterolemia, hypertriglyceridemia, fasting hyperglycemia, and hyperinsulinemia, which are characteristic of the profile often observed in patients with MetS. Although ezetimibe did not significantly change fasting glucose, IPGTT data strongly indicate that ezetimibe improved insulin sensitivity. Available for Android and iOS devices. Side effects requiring immediate medical attention. Ezetimibe (10 mg/day) was given to 17 patients with NAFLD for 6 months. This is when you have too much of a fatty substance called cholesterol in your blood. Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine Symptoms can include:If you develop these symptoms, call 911 or go to the nearest emergency room.Talk to your doctor if you’re pregnant or planning to become pregnant. © 2005-2020 Healthline Media a Red Ventures Company. Take the medicine at the same time each day.Ezetimibe may be taken at the same time with fenofibrate, or with a statin medication such as atorvastatin, lovastatin, simvastatin, pravastatin, or fluvastatin.If you also take cholestyramine, colestipol, or colesevelam: You may take ezetimibe 2 hours before taking any of these medicines or wait at least 4 hours after taking any of these other medicines.You may need frequent blood tests to check your liver function if you take ezetimibe with a statin medicine.It may take up to 2 weeks before your cholesterol levels improve. This medicine will not be as effective in lowering your cholesterol if you do not follow a cholesterol-lowering diet plan.Some cholesterol medications can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. , Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates, Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ, Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model, Reply to comment on: Effects of ezetimibe/simvastatin combination on metabolic parameters by Prof. Moses S Elisaf, Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease, Reactive Oxygen Species in Biology and Human Health, Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis, Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia, Ezetimibe Stimulates Intestinal Glucagon-Like Peptide 1 Secretion Via the MEK/ERK Pathway Rather Than Dipeptidyl Peptidase 4 Inhibition, Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia, A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia, Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia, Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?, Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease, Recent insights on the role of cholesterol in non-alcoholic fatty liver disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats, Overexpression of NPC1L1 in the livers of transgenic Bama miniature pigs accelerates lipid peroxidation, Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications, Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway, Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease, Biochemical and Biophysical Research Communications, Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease, Ezetimibe prevents the development of non-alcoholic fatty liver disease induced by high-fat diet in C57BL/6J mice, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial, The Niemann-Pick C1 Like 1 (NPC1L1) Inhibitor Ezetimibe Improves Metabolic Disease Via Decreased Liver X Receptor (LXR) Activity in Liver of Obese Male Mice, Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH), Acceleration of Biliary Cholesterol Secretion Restores Glycemic Control and Alleviates Hypertriglyceridemia in Obese db/db Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance, Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes Mellitus: Results of a Randomized Controlled Trial, Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet, American Journal of Physiology-Endocrinology and Metabolism, Nutrition and Alcoholic and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol, Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake, Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis, Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH), Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo, Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol, The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load, Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice, N-Acetylglucosaminyltransferase V regulates TGF-β response in hepatic stellate cells and the progression of steatohepatitis, Effect of Ezetimibe on Remnant-Like Particle Cholesterol in Subjects with Metabolic Syndrome, Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia, Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance, American Journal of Physiology-Gastrointestinal and Liver Physiology, Nonalcoholic fatty liver disease: from lipid profile to treatment, Double-Blind Randomized Clinical Trial of the Effects of Ezetimibe on Postprandial Hyperlipidaemia and Hyperglycaemia, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials, Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis, Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model, Biochemical and Biophysical Research Communications, Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake, Influence of ezetimibe monotherapy on ischemia-modified albumin levels in hypercholesterolemic patients, Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport, SREBP2 mediates the modulation of intestinal NPC1L1 expression by curcumin, American Journal of Physiology-Gastrointestinal and Liver Physiology, Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation, Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes, Biochemical and Biophysical Research Communications, Melanocortin 4 Receptor–Deficient Mice as a Novel Mouse Model of Nonalcoholic Steatohepatitis, Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet, American Journal of Physiology-Gastrointestinal and Liver Physiology, Effective Therapy Using Voglibose for Nonalcoholic Steatohepatitis in a Patient with Insufficient Dietary and Exercise Therapy: Exploring Other Treatment Possibilities, In vitro screening for antihyperlipidemic activities in foodstuffs by evaluating lipoprotein profiles secreted from human hepatoma cells, Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet, Effects of Adiposity on Plasma Lipid Response to Reductions in Dietary Saturated Fatty Acids and Cholesterol, Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease, Update on the efficacy and safety of combination ezetimibe plus statin therapy, Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia, Pleiotropic effects of ezetimibe: Do they really exist?, Ezetimibe and recent clinical trials: a look on the bright side, Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet, Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis, Effects of ezetimibe on glucose metabolism in patients with type 2 diabetes: A 12-week, open-label, uncontrolled, pilot study, The Effects of Ezetimibe on Surrogate Markers of Cholesterol Absorption and Synthesis in Japanese Patients with Dyslipidemia, Ezetimibe Ameliorates Metabolic Disorders and Microalbuminuria in Patients with Hypercholesterolemia, Dietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1,